<!DOCTYPE html lang="EN">
<html>
<head>
	
	<meta content="text/html; charset=UTF-8" http-equiv="Content-Type" />
	<title>Hormonal Replacement in Hypopituitarism in Adults_2017</title>
	<meta content="width=device-width; initial-scale=1.0; maximum-scale=1.5; user-scalable=1;" name="viewport" />
	<link charset="UTF-8" href="ENAS5297.css" rel="STYLESHEET" type="text/css" />
	<link charset="UTF-8" href="HighLight.css" rel="STYLESHEET" type="text/css" /><script src="jquery-2.0.31.min.js"></script><script type = "text/javascript" src = "HighlightSearch.js"></script>
	 <link rel="stylesheet" type="text/css" href="calci_std.css">
	 <link rel="stylesheet" type="text/css" href="ENAS5329.css">
</head>
<body onload="_geturl1();">

<table class="table">
	<colgroup>
		<col width="30%" />
		<col width="70%" />
	</colgroup>
	<tbody>
		<tr>
			<th class="table-header1" colspan="2">
			<p class="table-title1">Table 6 Doses of an&shy;tiplatelet and an&shy;ti&shy;co&shy;ag&shy;u&shy;lant co-&zwj;ther&shy;a&shy;pies in pa&shy;tients un&shy;der&shy;going pri&shy;ma&shy;ry per&shy;cu&shy;ta&shy;neous coro&shy;nary in&shy;ter&shy;ven&shy;tion or not reper&shy;fused</p>
			</th>
		</tr>
		<tr>
			<th class="table-header2" colspan="2">
			<p class="table-title2">Doses of an&shy;tiplatelet and par&shy;enter&shy;al an&shy;ti&shy;co&shy;ag&shy;u&shy;lant co-&zwj;ther&shy;a&shy;pies in pri&shy;ma&shy;ry PCI</p>
			</th>
		</tr>
		<tr>
			<th class="table-header3" colspan="2">
			<p class="table-title3">An&shy;tiplatelet ther&shy;a&shy;pies</p>
			</th>
		</tr>
		<tr>
			<td class="col-purple">
			<p class="table-text">As&shy;pirin</p>
			</td>
			<td class="col-purple">
			<p class="table-text">Load&shy;ing dose of 150&ndash;300 mg oral&shy;ly or of 75&ndash;250 mg <span class="italic">i.v.</span> if oral in&shy;ges&shy;tion is not pos&shy;si&shy;ble, fol&shy;lowed by a main&shy;te&shy;nance dose of 75&ndash;100 mg/&zwj;day.</p>
			</td>
		</tr>
		<tr>
			<td>
			<p class="table-text">Clopi&shy;do&shy;grel</p>
			</td>
			<td>
			<p class="table-text">Load&shy;ing dose of 600 mg oral&shy;ly, fol&shy;lowed by a main&shy;te&shy;nance dose of 75 mg/&zwj;day.</p>
			</td>
		</tr>
		<tr>
			<td class="col-purple">
			<p class="table-text">Pra&shy;sug&shy;rel</p>
			</td>
			<td class="col-purple">
			<p class="table-text">Load&shy;ing dose of 60 mg oral&shy;ly, fol&shy;lowed by a main&shy;te&shy;nance dose of 10 mg/&zwj;day</p>

			<p class="table-text">In pa&shy;tients with body weight &le;60 kg, a main&shy;te&shy;nance dose of 5 mg/&zwj;day is rec&shy;om&shy;mend&shy;ed.</p>

			<p class="table-text">Pra&shy;sug&shy;rel is con&shy;tra-&zwj;in&shy;di&shy;cat&shy;ed in pa&shy;tients with pre&shy;vi&shy;ous stroke. In pa&shy;tients &ge;75 years, pra&shy;sug&shy;rel is gen&shy;er&shy;ally not rec&shy;om&shy;mend&shy;ed, but a dose of 5 mg/&zwj;day should be used if treat&shy;ment is deemed nec&shy;es&shy;sary.</p>
			</td>
		</tr>
		<tr>
			<td>
			<p class="table-text">Tica&shy;grelor</p>
			</td>
			<td>
			<p class="table-text">Load&shy;ing dose of 180 mg oral&shy;ly, fol&shy;lowed by a main&shy;te&shy;nance dose of 90 mg <span class="italic">b.i.d</span>.</p>
			</td>
		</tr>
		<tr>
			<td class="col-purple">
			<p class="table-text">Ab&shy;cix&shy;imab</p>
			</td>
			<td class="col-purple">
			<p class="table-text">Bolus of 0.25 mg/kg <span class="italic">i.v.</span> and 0.125 μg/&zwj;kg/&zwj;min in&shy;fu&shy;sion (max&shy;i&shy;mum 10 μg/min) for 12 hours.</p>
			</td>
		</tr>
		<tr>
			<td>
			<p class="table-text">Ep&shy;ti&shy;fi&shy;batide</p>
			</td>
			<td>
			<p class="table-text">Dou&shy;ble bolus of 180 μg/kg <span class="italic">i.v.</span> (given at a 10-min in&shy;ter&shy;val) fol&shy;lowed by an in&shy;fu&shy;sion of 2.0 μg/&zwj;kg/&zwj;min for up to 18 hours.</p>
			</td>
		</tr>
		<tr>
			<td class="col-purple">
			<p class="table-text">Tirofiban</p>
			</td>
			<td class="col-purple">
			<p class="table-text">25 μg/kg over 3 min <span class="italic">i.v.</span>, fol&shy;lowed by a main&shy;te&shy;nance in&shy;fu&shy;sion of 0.15 μg/&zwj;kg/&zwj;min for up to 18 hours.</p>
			</td>
		</tr>
		<tr>
			<th class="table-header3" colspan="2">
			<p class="table-title3">Par&shy;enter&shy;al an&shy;ti&shy;co&shy;ag&shy;u&shy;lant ther&shy;a&shy;pies</p>
			</th>
		</tr>
		<tr>
			<td>
			<p class="table-text">UFH</p>
			</td>
			<td>
			<p class="table-text">70&ndash;100 IU/kg <span class="italic">i.v.</span> bolus when no GP IIb/&zwj;IIIa in&shy;hibitor is planned</p>

			<p class="table-text">50&ndash;70 IU/kg <span class="italic">i.v.</span> bolus with GP IIb/&zwj;IIIa in&shy;hibitors.</p>
			</td>
		</tr>
		<tr>
			<td class="col-purple">
			<p class="table-text">Enoxa&shy;parin</p>
			</td>
			<td class="col-purple">
			<p class="table-text">0.5 mg/kg <span class="italic">i.v.</span> bolus.</p>
			</td>
		</tr>
		<tr>
			<td>
			<p class="table-text">Bi&shy;valirudin</p>
			</td>
			<td>
			<p class="table-text">0.75 mg/kg <span class="italic">i.v.</span> bolus fol&shy;lowed by <span class="italic">i.v.</span> in&shy;fu&shy;sion of 1.75 mg/&zwj;kg/&zwj;hour for up to hours after the pro&shy;ce&shy;dure.</p>
			</td>
		</tr>
		<tr>
			<th class="table-header2" colspan="2">
			<p class="table-title2">Doses of an&shy;tiplatelet and par&shy;enter&shy;al an&shy;ti&shy;co&shy;ag&shy;u&shy;lant ther&shy;a&shy;pies in pa&shy;tients not re&shy;ceiv&shy;ing reper&shy;fu&shy;sion ther&shy;a&shy;py</p>
			</th>
		</tr>
		<tr>
			<th class="table-header3" colspan="2">
			<p class="table-title3">An&shy;tiplatelet ther&shy;a&shy;pies</p>
			</th>
		</tr>
		<tr>
			<td>
			<p class="table-text">As&shy;pirin</p>
			</td>
			<td>
			<p class="table-text">Load&shy;ing dose of 150&ndash;300 mg oral&shy;ly fol&shy;lowed by a main&shy;te&shy;nance dose of 75&ndash;100 mg/&zwj;day.</p>
			</td>
		</tr>
		<tr>
			<td>
			<p class="table-text">Clopi&shy;do&shy;grel</p>
			</td>
			<td>
			<p class="table-text">Load&shy;ing dose of 300 mg oral&shy;ly, fol&shy;lowed by a main&shy;te&shy;nance dose of 75 mg/&zwj;day oral&shy;ly.</p>
			</td>
		</tr>
		<tr>
			<th class="table-header3" colspan="2">
			<p class="table-title3">Par&shy;enter&shy;al an&shy;ti&shy;co&shy;ag&shy;u&shy;lant ther&shy;a&shy;pies</p>
			</th>
		</tr>
		<tr>
			<td>
			<p class="table-text">UFH</p>
			</td>
			<td>
			<p class="table-text">Same dose as with fib&shy;ri&shy;nolyt&shy;ic ther&shy;a&shy;py (see <a href="ref_ENAS5329_6.3.2.0.html">Table 7</a>).</p>
			</td>
		</tr>
		<tr>
			<td class="col-purple">
			<p class="table-text">Enoxa&shy;parin</p>
			</td>
			<td class="col-purple">
			<p class="table-text">Same dose as with fib&shy;ri&shy;nolyt&shy;ic ther&shy;a&shy;py (see <a href="ref_ENAS5329_6.3.2.0.html">Table 7</a>).</p>
			</td>
		</tr>
		<tr>
			<td>
			<p class="table-text">Fon&shy;da&shy;parin&shy;ux</p>
			</td>
			<td>
			<p class="table-text">Same dose as with fib&shy;ri&shy;nolyt&shy;ic ther&shy;a&shy;py (see <a href="ref_ENAS5329_6.3.2.0.html">Table 7</a>).</p>
			</td>
		</tr>
	</tbody>
</table>

<br>
        <div style="float:right; width:70px; paddin:0px 0px 3px 0px;   ">
                <button id="pdf_button"  class="flip-pdf-button"  >
                    <a href="flipView"> <img src="algo.png" class="pdf-image "></img></a>
                </button>
        </div>
		<br/>
		 <div class="static-reference-box">
  <p class="text_left"><i>b.i.d.</i> = twice a day; GP = glycoprotein; <i>i.v.</i> = intravenous; IU = international units; PCI = percutaneous coronary
intervention; UFH = unfractionated heparin.
                       </p>
                        </div>
						 <div class="static-reference-box">
  <p class="text_left">*Doses of antiplatelet and parenteral anticoagulant co-therapies in
primary PCI<br/>**Doses of antiplatelet and parenteral anticoagulant therapies in
patients not receiving reperfusion therapy
                       </p>
                        </div>
     
</body>
</html>
